Nevertheless, a growing body of evidence suggests that the treatment of MR antagonists may improve clinical outcomes in dialysis patients without a significant increase in the risk of hyperkalemia [26, 29–32]. The gene discussed is NR3C2; the disease is Hyperkalemia.